SAN FRANCISCO, Feb. 8, 2012 /PRNewswire/ -- MAKO Surgical
Corp. (NASDAQ: MAKO), a leader in robotic arm assisted partial knee
arthroplasty worldwide, today announced the MAKOplasty® Total Hip
Arthroplasty (THA) application will be featured at the American
Academy of Orthopaedic Surgeons 2012 Annual Meeting (AAOS) being
held on February 7-11, 2012 at the
Moscone Center in San Francisco,
California.
MAKOplasty® THA is the newest application for MAKO's RIO®
Robotic Arm Interactive Orthopedic System. The RIO® system will be
on exhibit at MAKO's AAOS Annual Meeting Booth #2353. During the
meeting, experienced MAKOplasty® orthopedic surgeons will give
presentations and hands-on demonstrations of the MAKOplasty® THA
application.
"There is clearly a need for precision and accuracy in total hip
replacement. We believe the RIO® system, which enables
surgeons to achieve consistently reproducible precision for the
individual patient, along with our MAKOplasty® THA, are key drivers
in leading our growing presence in orthopedic surgery," said
Maurice R. Ferrė, M.D., president and CEO of MAKO.
MAKOplasty® THA builds upon MAKOplasty® Partial Knee
Resurfacing's proven benefits for patients with early to mid-stage
osteoarthritis of the knee. To date, nearly 13,000 patients have
benefited from MAKOplasty® partial knee and total hip procedures.
In 2012, MAKO anticipates to perform 11,000 to 13,000 MAKOplasty®
procedures.
MAKOplasty® THA was introduced in 2011 and is designed to
support a surgeon's ability to more accurately align and position a
hip implant relative to the specific needs of a patient. It
provides a surgeon with a pre-operative 3-D reconstruction of a
patient's hip that is used to develop a patient-specific surgical
plan. The surgeon then uses the RIO® robotic arm during the
procedure to prepare the joint and optimally place the hip implant
to the plan.
As of December 31, 2011, 49
MAKOplasty® THA applications have been sold in the U.S.; hospitals
in California, New York, and Florida are among many locations nationwide
now offering MAKOplasty® THA.
More information about MAKOplasty® can be found at
http://makoplasty.com.
About MAKO Surgical Corp.
MAKO Surgical Corp. is a medical device company that markets its
RIO® Robotic-Arm Interactive Orthopedic system, joint specific
applications for the knee and hip, and proprietary RESTORIS®
implants for orthopedic procedures called MAKOplasty®. The RIO is a
surgeon-interactive tactile surgical platform that incorporates a
robotic arm and patient-specific visualization technology, which
enables precise, consistently reproducible bone resection for the
accurate insertion and alignment of MAKO's RESTORIS implants. The
MAKOplasty solution incorporates technologies enabled by an
intellectual property portfolio including more than 300 U.S. and
foreign, owned and licensed, patents and patent applications.
Additional information can be found at www.makosurgical.com.
Forward-Looking Statements
This press release contains forward-looking statements
regarding, among other things, statements related to expectations,
goals, plans, objectives and future events. MAKO intends such
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Reform Act of 1995. In some cases, forward-looking statements can
be identified by the following words: "may," "will," "could,"
"would," "should," "expect," "intend," "plan," "anticipate,"
"believe," "estimate," "predict," "project," "potential,"
"continue," "ongoing," "guidance" or the negative of these terms or
other comparable terminology, although not all forward-looking
statements contain these words. Examples of such statements
include, but are not limited to, statements about the nature,
timing and number of planned new product introductions; market
acceptance of MAKOplasty, including the RIO system, and MAKO
RESTORIS® family of implant systems; the future availability from
third-party suppliers, including single source suppliers, of
implants for and components of the RIO system; the anticipated
adequacy of our capital resources to meet the needs of MAKO's
business; MAKO's ability to sustain, and MAKO's goals for, sales
and earnings growth including projections regarding systems
installations; and MAKO's success in achieving timely approval or
clearance of products with domestic and foreign regulatory
entities. These statements are based on the current estimates and
assumptions of our management as of the date of this press release
and are subject to risks, uncertainties, changes in circumstances,
assumptions and other factors that may cause actual results to
differ materially from those indicated by forward-looking
statements, many of which are beyond MAKO's ability to control or
predict. Such factors, among others, may have a material adverse
effect on MAKO's business, financial condition and results of
operations and may include the potentially significant impact of a
continued economic downturn or delayed economic recovery on the
ability of MAKO's customers to secure adequate funding, including
access to credit, for the purchase of MAKO's products or cause
MAKO's customers to delay a purchasing decision, changes in
competitive conditions and prices in MAKO's markets, unanticipated
issues relating to intended product launches, decreases in sales of
MAKO's principal product lines, decreases in utilization of MAKO's
principal product line or in procedure volume, increases in
expenditures related to increased or changing governmental
regulation or taxation of MAKO's business, both nationally and
internationally, unanticipated issues in complying with domestic or
foreign regulatory requirements related to MAKO's current products
or securing regulatory clearance or approvals for new products or
upgrades or changes to MAKO's current products, the impact of the
recently enacted United States
healthcare reform legislation on hospital spending, reimbursement,
and the taxing of medical device companies, the potential impact of
the informal Securities and Exchange Commission inquiry and the
findings of that inquiry, loss of key management and other
personnel or inability to attract such management and other
personnel and unanticipated intellectual property expenditures
required to develop, market, and defend MAKO's products. These and
other risks are described in greater detail under Item 1A, "Risk
Factors," in MAKO's periodic filings with the Securities and
Exchange Commission, including MAKO's annual report on Form 10-K
for the year ended December 31, 2010
filed on March 10, 2011 and quarterly
report on Form 10-Q for the quarter ended September 30, 2011 filed on November 9, 2011. Given these uncertainties,
undue reliance should not be placed on these forward-looking
statements. MAKO does not undertake any obligation to release any
revisions to these forward-looking statements publicly to reflect
events or circumstances after the date of this press release or to
reflect the occurrence of unanticipated events.
"MAKOplasty®," "RESTORIS®," "RIO®," as well as the "MAKO" logo,
whether standing alone or in connection with the words "MAKO
Surgical Corp." are trademarks of MAKO Surgical Corp.
SOURCE MAKO Surgical Corp.